← Leaderboards
Andrea D. Branch
Mount Sinai School Of Medicine Of Nyu
$14,715,515
Attributed
$17,058,994
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,489,015 · 7
CDC$5,569,979 · 4
By mechanism
R01$9,714,301 · 5
U01$6,766,400 · 4
R21$578,293 · 2
Top collaborators
- Douglas Thomas Dieterich5 shared
- Richard K. Sterling3 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Douglas Thomas Dieterich$1,765,604
Others in their field
Top investigators on “Hepatitis C Virus”
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,575,784
- Peter B. Gilbert · Fred Hutchinson Cancer Center$77,122,577
- Robert Turner Schooley · University Of Colorado Denver$45,719,253
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
- Charles M. Rice · Rockefeller University$42,549,577
Research focus
Hepatitis C VirusResponseGene ExpressionInterferonsMutationMalignant Neoplasm Of LiverBaseGenesPathway InteractionsCore ProteinLiver DiseasesProteinsResearch StudyAntibodiesPublishingMolecularViralFutureClinical ResearchInsightProductionAntiviral AgentsCancer EtiologyLiver
Grant awards (42)
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$682,915
U01 · FY2025 · CA · contact PI
Racial and Ethnic Disparities in Liver Disease in the WTC General Responder Cohort$499,998
U01 · FY2025 · OH · contact PI
The Liver, Metabolic Syndrome, and Increased CVD risk among African American World Trade Center General Responders$172,764
R21 · FY2025 · OH · contact PI
Racial and Ethnic Disparities in Liver Disease in the WTC General Responder Cohort$499,995
U01 · FY2024 · OH · contact PI
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$325,920
U01 · FY2024 · CA · contact PI
Racial and Ethnic Disparities in Liver Disease in the WTC General Responder Cohort$499,999
U01 · FY2023 · OH · contact PI
Evidence of Toxicant-associated Fatty Liver Disease in WTC Responders$499,346
U01 · FY2023 · OH · contact PI
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture$360,350
U01 · FY2023 · CA · contact PI
Evidence of Toxicant-associated Fatty Liver Disease in WTC Responders$499,759
U01 · FY2022 · OH · contact PI
Evidence of Toxicant-associated Fatty Liver Disease in WTC Responders$499,043
U01 · FY2021 · OH · contact PI
Hepatotoxic Exposures, Progressive Fatty Liver Disease (NASH), and Liver Cancer Risk in the World Trade Center Health Program General Responder Cohort$599,768
U01 · FY2020 · OH · contact PI
Hepatotoxic Exposures, Progressive Fatty Liver Disease (NASH), and Liver Cancer Risk in the World Trade Center Health Program General Responder Cohort$599,769
U01 · FY2019 · OH · contact PI
Hepatotoxic Exposures, Progressive Fatty Liver Disease (NASH), and Liver Cancer Risk in the World Trade Center Health Program General Responder Cohort$599,769
U01 · FY2018 · OH · contact PI
Hepatotoxic Exposures, Progressive Fatty Liver Disease (NASH), and Liver Cancer Risk in the World Trade Center Health Program General Responder Cohort$599,769
U01 · FY2017 · OH · contact PI
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$662,522
R01 · FY2014 · DA · contact PI
Clinical Outcomes and the HCV Core Gene$348,195
R01 · FY2014 · DK · contact PI
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$611,032
R01 · FY2013 · DA · contact PI
Clinical Outcomes and the HCV Core Gene$336,008
R01 · FY2013 · DK · contact PI
Clinical Outcomes and the HCV Core Gene$72,055
R01 · FY2013 · DK · contact PI
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$659,845
R01 · FY2012 · DA · contact PI
Clinical Outcomes and the HCV Core Gene$418,046
R01 · FY2012 · DK · contact PI
HCV Strain Variation and HCC$184,331
R21 · FY2012 · CA · contact PI
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$678,246
R01 · FY2011 · DA · contact PI
Clinical Outcomes and the HCV Core Gene$348,195
R01 · FY2011 · DK · contact PI
HCV Strain Variation and HCC$221,198
R21 · FY2011 · CA · contact PI
Clinical Outcomes and the HCV Core Gene$69,851
R01 · FY2011 · DK · contact PI
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$706,128
R01 · FY2010 · DA · contact PI
Clinical Outcomes and the HCV Core Gene$423,750
R01 · FY2010 · DK · contact PI
Modulation of HCV Gene Expression$100,000
R01 · FY2010 · DK · contact PI
Modulation of HCV Gene Expression$370,132
R01 · FY2008 · DK · contact PI
Modulation of HCV Gene Expression$377,685
R01 · FY2007 · DK · contact PI
HCV Alternate Reading Frame Protein in HIV/HCV Co-infect$361,611
R01 · FY2007 · DA · contact PI
Modulation of HCV Gene Expression$388,965
R01 · FY2006 · DK · contact PI
HCV Alternate Reading Frame Protein in HIV/HCV Co-infect$372,412
R01 · FY2006 · DA · contact PI
Modulation of HCV Gene Expression$398,325
R01 · FY2005 · DK
HCV Alternate Reading Frame Protein in HIV/HCV Co-infect$381,375
R01 · FY2005 · DA
Modulation of HCV Gene Expression$394,797
R01 · FY2004 · DK
HCV Alternate Reading Frame Protein in HIV/HCV Co-infect$381,375
R01 · FY2004 · DA
HCV Alternate Reading Frame Protein in HIV/HCV Co-infect$379,151
R01 · FY2003 · DA
RIBOZYMES AND RNA GENE THERAPIES FOR LIVER DISEASES$135,600
R01 · FY2003 · DK
RIBOZYMES AND RNA GENE THERAPIES FOR LIVER DISEASES$169,500
R01 · FY2001 · DK
RIBOZYMES AND RNA GENE THERAPIES FOR LIVER DISEASES$169,500
R01 · FY2000 · DK